rare diseases treatment 

Economy China bans export of Korean goods containing its rare earth metals to US

The Chinese government has warned South Korean companies of retributions for exporting any product containing its critical metals to US military con...

Bio & Pharma Celltrion wins Australian approval for eye, bone disease biosimilars

Celltrion Inc. said Wednesday it has received regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for three biosimilar...

Korean Investors Samsung to invest $10 million in US-based C2N Diagnostics

Samsung Group companies will jointly invest $10 million in C2N Diagnostics LLC, a U.S.-based company specializing in blood-based Alzheimer’s d...

Bio & Pharma Celltrion wins EU approval for autoimmune disease treatment Avtozma

Celltrion Inc.’s Avtozma, a biosimilar to Roche’s autoimmune disease treatment Actemra, has won approval from the European Commission, f...

Corporate restructuring SK Ecoplant seeks to sell waste treatment business for $1.4 billion

SK Ecoplant Co., a South Korean construction engineering and waste management company under SK Group, is seeking to dispose of its waste treatment b...

Mergers & Acquisitions LG Chem embarks on sale of dermal filler business worth $343 million

LG Chem Ltd., the world’s fourth-largest chemicals producer that is fostering vaccine and new drug development as new growth drivers, has kick...

Bio & Pharma Celltrion’s Vegzelma: Most-prescribed cancer treatment in Europe

South Korea’s leading biosimilar drug developer Celltrion Inc.'s Vegzelma, a cancer drug referencing global biopharma Roche’s Avastin, h...

Batteries SK Ecoplant, BMW team up for battery recycling

SK Ecoplant Co., a South Korean construction engineering and waste management company under SK Group, partnered with German luxury carmaker BMW to...

Bio & Pharma Yuhan’s lung cancer drug gets OK in Europe

Leclaza (ingredient: lazertinib), a new lung cancer treatment developed by South Korea’s Yuhan Corp. secured approval from the European Commis...

Bio & Pharma Celltrion obtains approval of Steqeyma from FDA

South Korea's Celltrion Inc. said on Wednesday it received new drug submission (NDS) approval from the Food and Drug Administration (FDA) for Steq...

Bio & Pharma SK Pharmteco bags obesity treatment deal worth up to $1.4 bn

SK Pharmteco Co., a contract development and manufacturing organization (CDMO), has secured an obesity treatment order worth up to 2 trillion won ($...

Bio & Pharma Celltrion gets approval of Omlyclo in Canada

South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Omlyclo, the biosimilar of allergic asthma an...

Bio & Pharma Celltrion releases Steqeyma in Europe

South Korea's Celltrion Inc. said on Monday it released Steqeyma (ustekinumab) in Europe, the biosimilar of autoimmune disease treatment Stelara.T...

Bio & Pharma Celltrion's Zymfentra gets 90% distribution channel in US

South Korean biosimilar maker Celltrion Inc. said on Monday its subcutaneous injection formulation for autoimmune diseases, Zymfentra (infliximab), ...

Energy DS Dansuk wins $750 mn SAF material order from Phillips 66

South Korea's DS Dansuk Co., which operates bioenergy, battery, and plastic recycling businesses, said on Monday it signed a 1 trillion won ($750 mi...

Bio & Pharma ViGenCell obtains approval for HLA-B5801 genetic diagnostic kit for adverse reactions to gout treatment

ViGenCell, a company specializing in immunotherapy, announced on Friday that it has obtained approval from the Ministry of Food and Drug Safety (MFD...

Bio & Pharma Celltrion's anti cancer drugs hold 90% market share in C.America

South Korea’s Celltrion Inc. said on Friday that its cancer treatments have captured a 90% market share in several Central American countries....

Bio & Pharma Osstem Implant to boost digital dentistry business

South Korea's Osstem Implant Co., the world’s fourth-largest dental implant maker, will enhance its software system of digital dentistry. ...

Bio & Pharma Celltrion to supply breast, stomach cancer treatment to Brazil

Celltrion Inc., South Korea’s largest biosimilar maker, announced on Friday that its breast and stomach cancer treatment "Herzuma" (active ing...

Bio & Pharma SK Group’s 3rd-generation daughter comes to the fore

Chey Yoon-chung, the eldest daughter of SK Group Chairman Chey Tae-won, unexpectedly made her debut during an SK Biopharmaceuticals Co. video confer...

Bio & Pharma IMBiologics transfers autoimmune disease drug tech to Huadong Pharma

South Korea's antibody-based biotech company IMBiologics announced on Friday that it signed a contract to transfer the technology of its autoimmune ...

Mergers & Acquisitions GS E&C in talks to sell entire stake in GS Elevator to Chinese firm

South Korea’s GS Engineering & Construction Corp. (GS E&C) is in talks to sell its entire stake in GS Elevator Co. to a Chinese strate...

Bio & Pharma Costco sells Celltrion's Yuflyma Low WAC in US

South Korea's Celltrion Inc. announced on Tuesday that its autoimmune disease treatment Yuflyma (Low WAC, active ingredient adalimumab) is now avail...

Bio & Pharma Celltrion gets approval of Steqeyma in Canada

South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Steqeyma, a biosimilar of the autoimmune dise...

Bio & Pharma GC Biopharma sells HK subsidiary to CR Pharm Group for $254 mn

South Korea’s GC Biopharma Corp. announced on Wednesday that it signed a share purchase agreement (SPA) to sell all its shares in its Hong Kon...

North Korea A North Korean Diplomat Managed a Rare Defection: A Flight Out of Cuba

SEOUL—A North Korean diplomat posted in Cuba defected to South Korea with his family late last year, officials said this week, a rare esc...

Bio & Pharma LG Chem launches Synovian in China

South Korea's LG Chem Ltd. announced on Wednesday that it launched its homegrown new drug for osteoarthritis Synovian (marketed in China as Hyruan O...

Electric vehicles Korea Eximbank to provide $150 mn PF to Australia

The Export-Import Bank of Korea (Eximbank) announced on Tuesday that it will provide $150 million in project financing (PF) for developing a rare ea...

Bio & Pharma Handok gets Biocon's obesity drug exclusive distribution in S.Korea

South Korean pharmaceutical company Handok Inc. announced on Friday that it signed an exclusive domestic sales and distribution agreement with India...

Electric vehicles Hyundai Motor, Kia to develop alternative to rare earth materials

Hyundai Motor Co. and Kia Corp. have partnered with South Korea's universities to secure materials for vehicle electrification components.Hyundai Mo...